Immunotherapy has transformed advanced melanoma from a terminal diagnosis into a manageable disease for thousands of Australians. But behind the clinical success stories lies a devastating reality - the treatment comes with a built-in expiration date for many patients.
When the immune system is driven to continuously attack a stubborn tumour, it triggers a state of "T cell exhaustion." The T cells, the frontline soldiers of the immune system, eventually become deeply fatigued and lose their ability to kill cancer cells, rendering the world's most advanced therapies effectively useless. For these patients, the options have been grim.
This Melanoma March, groundbreaking research led by Professor Kristen Radford at Mater Research offers profound new hope, delivering a one-two punch that could finally shatter the immunotherapy ceiling.
In two high-impact studies published recently in OncoImmunology and Cancer Immunology Research, Prof Radford’s team—in collaboration with leading international experts—has unveiled a new generation of "DC1" cancer vaccines capable of revitalising these exhausted immune systems.
Prof Radford said that the team first needed to develop a reliable model that mimics T cell exhaustion found in human melanoma so they could find a way to wake these fatigued immune cells back up.
In their first publication in OncoImmunology, the researchers detailed their development of a highly advanced, reliable humanised mouse model that successfully mimics the complex human tumour microenvironment.
The team found that introducing conventional Type 1 Dendritic Cells (cDC1) - often referred to as the master regulators of the immune system - into the model boosted the T cells' ability to kill tumour cells, definitively halting tumour growth.
Prof Radford said that while cDC1s are incredibly potent, they are exceptionally rare in human blood.
“Historically, this has made it nearly impossible to manufacture them into viable cellular vaccines for patients,” Prof Radford said.
“This has long prevented this type of therapy from reaching the clinic.”
This critical manufacturing bottleneck was solved through a landmark international collaboration with the Icahn School of Medicine at Mount Sinai in New York—a partnership that was forged from Professor Radford’s 2021 Fulbright Future Scholarship.
Published in Cancer Immunology Research late last year, the collaborative team revealed a novel serum-free culture system capable of generating billions of human cDC1s from stem cells. By harnessing a biological pathway known as "Notch signalling," the researchers successfully produced functionally potent cDC1s on a massive scale.
The dual findings dismantle the two biggest barriers to next-generation melanoma treatment. The Mount Sinai collaboration secures the supply chain, proving these elusive cells can finally be mass-produced for human trials. Crucially, the OncoImmunology data demonstrates that, once administered, the vaccines can successfully override the biological exhaustion that causes patients to relapse.
For the thousands of patients whose immune systems have become too exhausted to fight, this Australian-led innovation serves as a powerful reminder of how relentless scientific inquiry and global collaboration are bringing us closer to a lasting cure for advanced melanoma.
The original papers, titled “Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes” and “Harnessing Notch Signaling to Enhance the Generation and Functionality of Human Conventional Type 1 Dendritic Cells for Cancer Immunotherapy Applications” were both published in 2025.
